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Abstract. 
We present two renal cell carcinoma (RCC) cases with rapid disease progression within 
one month of an interventional procedure. Analysis of the clinical courses and laboratory data 
suggested that a burst of inflammatory cytokines following the procedures could have been the 
main reason for cancer progression. Higher tumor burden and the presence of paraneoplastic 
syndrome could be indicators predicting such a complication. Although the mechanism is not 
well understood, identifying such patients is important. 
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中文摘要 
  腎細胞癌本身疾病進展緩慢，但本次報告內容則提出因檢查而導致腫瘤快速進展的
特殊個案。根據病患的血液檢查，推測可能與發炎性細胞激素誘導有關，而容易引起大
量細胞激素釋放的相關因子有診斷時腫瘤大小與是否有腫瘤附屬症候群相關，但準確之
原因仍需進一步探討。臨床上遇到此類患者在安排檢查時須特別注意。 
 
關鍵字: 腎細胞癌、檢查引發之併發症 
INTRODUCTION 
Accelerated cancer progression after local treat-
ment has been previously reported in different types of 
cancer. Seki T et al. presented a hepatocellular carci-
noma case whose condition deteriorated rapidly after 
undergoing locoregional therapy [1]. Tomoki Yamano 
et al. presented a case of gastric cancer progressing 
rapidly within three months of endoscopic biopsy [2]. 
No similar reports have been reported in renal cell 
carcinoma (RCC), although studies have focused on 
the risk factors of rapid progression following ne-
phrectomy [3]. It is crucial for every clinical practi-
tioner to explain the potential complications to the 
patient before a procedure. As a reminder of potential 
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 complications, we report two patients with RCC 
showing extremely rapid progression after a relatively 
simple procedure. 
 
CASE REPORTS 
 
Case 1 
A 43-year-old male patient was transferred to our 
hospital for histopathological diagnosis of a huge right 
renal tumor on November 11, 2011. Hepatitis C and 
alcohol related liver cirrhosis had been diagnosed 5 
years earlier. His liver reserve and performance status 
were satisfactory when the renal tumor was diagnosed. 
Computed tomography (CT) revealed local advanced 
disease without distant metastasis. His laboratory data 
disclosed paraneoplatic syndrome, including anemia 
(hemoglobin: 10.8 (g/dL)) and borderline elevated 
C-reactive protein (4.043 mg/L). CT-guided fine nee-
dle biopsy was arranged for histological diagnosis. 
Just after biopsy, he developed lethargy, tachypnea 
(respiratory rate: 25/min), pyrexia, and mild hemopty-
sis. A slight rise in the C-reactive protein level (13.16 
mg/L) was noted. A chest radiography revealed diffuse 
lung nodules (Figures 1A and 1B). An empiric antibi-
otic was prescribed because an infection, such as from 
a septic emboli, was suspected. The result of the first 
kidney biopsy was negative for malignancy, so a se-
cond fine needle biopsy was done on November 23, 
2011. The final pathology showed RCC, clear cell 
type (Figures 1C and 1D). In the early morning of 
November 24, his condition deteriorated and he re-
quired full mechanical ventilator support in the inten-
sive care unit. A follow-up CT revealed disseminated 
lung and brain metastases (Figure 2). Bronchoscopic 
biopsy was suggested, but the patient’s family de-
clined due to the risk of this procedure. The patient 
died of multiple organ failure on the 25th day after 
admission. 
 
Case 2 
A 45-year-old male patient had a left RCC diag-
nosed in January 2010. His initial tumor staging was 
stage IV with lumbar spine metastasis. Before he re-
ceived anti-cancer therapy, he was admitted for epi-
gastric pain. Physical examination disclosed no re-
markable findings. The laboratory data revealed para-
neoplatic syndrome, including leukocytosis (white cell 
count: 30.1 (103/uL)), anemia (hemoglobin: 11.9 
(g/dL)), and elevated C reactive protein level (272.73 
mg/L). Panendoscopy showed multiple gastric ulcers. 
Eight hours after the procedure, spiking fever, chill-
ness, and conscious disturbance developed. Because 
of respiratory failure, he was intubated and transferred 
to the intensive care unit. Chest radiography post in-
tubation showed multiple pulmonary nodules and a 
left pleural lesion (Figures 1E and 1F). The follow-up 
CT also confirmed rapid cancer progression (Figure 3). 
Pluera biopsy and pericardial effusion examination 
revealed atypical cells. However, because the samples 
were too small, further special staining could not per-
formed. His condition deteriorated and he died of 
multiple organ failure on the 15th day after admission. 
 
DISCUSSION 
These two cases suggest the possibility of proce-
dure-induced rapid RCC progression. Although final 
pathological confirmation of the metastatic sites could 
not be obtained, there were several reasons indicating 
that the deterioration of the patients' condition was 
associated with tumor progression. First, serial imag-
ing studies showed rapid progression and even newly 
developed lesions (Figures 1-3). Both patients died 
due to target organ involvement, such as the heart, 
lung and brain. Second, the evidence of infection was  
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Figure 1. Pre-procedure (A) and post-procedure (B) chest radiography of case 1. Pathology 
in case 1 was renal cell carcinoma, clear cell type (C and D). Pre-procedure (E) 
and post-procedure (F) chest radiography of case 2 
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Figure 2. Computed tomography images for case 1: bilateral lung metastases (A-C) and multiple brain 
nodules (D-F) 
 
 
insufficient, not only because the culture results were 
negative, but also because the infection foci could not 
be determined. Third, the initial and final laboratory 
data showed paraneoplastic syndrome rather than ac-
tive infection. Komai et al. reported that preoperative 
serum C-reactive protein could predict the prognosis 
of localized RCC [4]. Thus, based on the serum 
C-reactive protein levels, a correlation between the 
procedures and serum cytokine level could be found 
(Table 1). Patients with RCC frequently have parane- 
Table 1. Clinical course and laboratory data 
 Diagnosis Before procedure After procedure Procedure Date of death
Case 1 Renal cell 
carcinoma  
Hb: 10.8 g/dL 
CRP: 4.043 mg/L 
 
Hb: 8.2 g/dL 
CRP: 13.6 mg/L 
D-dimer: 5300 FEU ng/mL 
Fine needle biopsy, 
the 3rd day of 
admission 
The 25th day 
Case 2 Renal cell 
carcinoma  
WBC: 30000/uL 
Hb: 8.7 g/dL 
CRP: 272.73 mg/L 
WBC: 47200/uL 
Hb: 9.1 g/dL 
CRP: 297 mg/L 
D-dimer: >10000 FEU ng/mL
Panendoscopy, the  
1st day of admission 
The 15th day 
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Figure 3. Computed tomography images for case 2 showing metastases to lung, left pleura, lumbar spine, 
abdominal nodes and left psoas muscle (A: left pleural mass, B: multiple lung nodules, C: left 
pleural mass, D: left infiltrating psoas mass and multiple abdominal nodes, E: left infiltrating 
psoas mass with bony structure involvement, F: left infiltrating psoas mass extending to sacral 
area) 
 
 
oplatic syndrome, which may due to the higher level 
of circulating interleukin-6 or other cytokines [5]. This 
supported our hypothesis that tumor progression af-
fected survival in both patients.  
It is crucial to figure out which types of RCC 
would have such kind of progression pattern and how 
this risk is induced. There were similar characteristics 
in both patients, including male gender, large tumor 
burden or advanced stage, and the presence of para-
neoplastic syndrome. However, there was no direct 
evidence linking the procedures with RCC progres-
sion. Dysregulation of signaling pathways could ex-
plain tumor progression in these cases. RCC has been 
reported to be related to the hypoxia-inducible path-
way [6]. Stimuli from a procedure could induce tran-
sient hypoxia, which in turn could trigger hypoxia re-
sponsive gene transcription. Stimulation of hypoxia 
indicible trascription factors, such as vascular endo-
thelial growth factor, may lead to rapid tumor pro-
gression [7,8]. Alternatively, the NF-κB pathway is 
also known to be involved in the pathogenesis of RCC, 
and it could be activated and amplified by a hypoxia 
event [9]. NF-κB plays a critical role in explaining 
tumor progression because of its association with cy-
tokines, such as interleukin-6, which are related to 
paraneoplastic syndrome [5,10]. Both cases displayed 
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 paraneoplastic syndrome at first diagnosis. A rise in 
cytokine secretion may occur after a procedure, which 
could also explain tumor progression. However, RCC 
is a biologically complex disease. Papillary RCC, for 
example, is associated with the mesenchymal epitheli-
al transition pathway rather than the hypoxia inducible 
pathway [11]. Thus, it is important to determine which 
kind of event is associated with which pathway. 
Elucidating the mechanisms of tumor progression 
could help the identification of possible preventive 
strategies. The use of anti-vascular epithelial growth 
factor agent as a prophylactic agent is not considered 
because of its cost and uncertain efficacy. However, 
corticosteroids have been used as a treatment modality 
under the hypothesis of NF-κB, so could serve as a 
prophylactic agent [10,12]. However, the efficacy of 
prophylactic treatment is not yet known, and further 
studies in this field are necessary. 
In conclusion, we report two cases of procedure- 
induced RCC progression. Even though the mecha-
nism is not fully understood, physicians should be 
aware of this possibility in their management of RCC 
patients. 
 
Acknowledgments: The authors would like to thank Dr. Liang- 
Che Chang for reviewing pathology 
 
REFERENCES 
1. Seki T, Tamai T, Ikeda K, et al. Rapid progression 
of hepatocellular carcinoma after transcatheter 
arterial chemoembolization and percutaneous ra-
diofrequency ablation in the primary tumour re-
gion. Eur J Gastroenterol Hepatol 13: 291-4, 
2001. 
2. Yamano T, Morii E, Ikeda J, et al. Granulocyte 
colony-stimulating factor production and rapid 
progression of gastric cancer after histological 
change in the tumor. Jpn J Clin Oncol 37: 793-6, 
2007.  
3. Leibovich BC, Blute ML, Cheville JC, et al. Pre-
diction of progression after radical nephrectomy 
for patients with clear cell renal cell carcinoma: a 
stratification tool for prospective clinical trials. 
Cancer 97: 1663-71, 2003. 
4. Komai Y, Saito K, Sakai K, et al. Increased pre-
operative serum C-reactive protein level predicts 
a poor prognosis in patients with localized renal 
cell carcinoma. BJU Int 99: 77-80, 2007. 
5. Blay JY, Rossi JF, Wijdenes J, et al. Role of inter-
leukin-6 in the paraneoplastic inflammatory syn-
drome associated with renal-cell carcinoma. Int J 
Cancer 72: 424-30, 1997. 
6. Finley DS, Pantuck AJ, Belldegrun AS. Tumor 
biology and prognostic factors in renal cell carci-
noma. Ocologist 16 Suppl 2: 4-13, 2011.  
7. Klatte T, Pantuck AJ. Molecular biology of renal 
cortical tumors. Urol Clin North Am 35: 573-80, 
2008. 
8. Vaupel P. The role of hypoxia-induced factors in 
tumor progression. Ocologist 9 Suppl 5: 10-7, 
2004. 
9. Eltzschig HK, Carmeliet P. Hypoxia and inflam-
mation. N Engl J Med 364: 656-65, 2011.  
10. Yamamoto Y, Gaynor RB. Therapeutic potential 
of inhibition of the NF-kappaB pathway in the 
treatment of inflammation and cancer. J Clin In-
vest 107: 135-42, 2001. 
11. Wadt KA, Gerdes AM, Hansen TV, et al. Novel 
germline c-MET mutation in a family with hered-
itary papillary renal carcinoma. Fam Cancer 11: 
535-7, 2012. 
12. Shinojima T, Oya M, Kohno H, et al. Dexame-
thasone and interleukin-2 combination therapy for 
advanced renal cell carcinoma in a patient with 
paraneoplastic inflammatory syndrome. Int J 
Urol 11: 553-6, 2004. 
 
62 Y. S. Chang et al./JCRP 1(2014) 57-62
